Drug discovery and development – Page 33
-
ResearchDual warhead kills and disarms bacteria
Compound damages bacterial membrane and disables resistance mechanism in a two-pronged attack
-
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
FeatureTargeting breast cancer
Tamoxifen has been treating breast cancer for 40 years, but few would have predicted how much this drug would contribute to saving lives, writes John Mann
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
-
-
-
ReviewIntroduction to biological and small molecule drug research and development
Big molecule pharma
-
NewsCroatia's vaccines manufacturer left hanging as it enters administration
Lack of government investment puts national immunology institute in crisis
-
OpinionIs there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
OpinionPut the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
-
OpinionNatural born chemists
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe
-
BusinessGSK to apply for malaria vaccine approval
Infection protection drops over time, but the firm will go ahead with regulatory submission
-
FeatureRe-arming the antibiotic arsenal
How can we make new antibiotics? Phillip Broadwith takes a look
-
CareersNon-profit pharma
Not-for-profit drug discovery is growing into a promising niche employment opportunity within the pharmaceutical industry. James Mitchell Crow investigates
-
BusinessService with a smile
Company profile: Charnwood Molecular is more than a run-of-the-mill contract synthesis provider
-
FeatureAnimal pharm
Making drugs to treat animals is potentially lucrative – but also difficult, as Clare Sansom discovers